| Literature DB >> 35164142 |
Guanlin Zhong1, Jiayi Shen1, Zhengwang Chen1, Zunxian Lin1, Lipeng Long1, Jiaying Wu1, Chenhuan Long1, Siyu Huang1, Ping Lian1, Guotian Luo1.
Abstract
Hesperetin is a class of natural products with a wide range of sources and remarkable biological activities. In this study, we described the synthesis of a series of novel hesperetin derivatives and evaluated the in vitro antioxidant and antitumor activity of these compounds. Eleven novel compounds were synthesized in moderate yields. The compounds synthesized in this work exhibited antioxidant activities against DPPH and ABTS free radicals in a dose-dependent manner. Among them, compound 3f had the best antioxidant activity, with IC50 of 1.2 μM and 24 μM for DPPH and ABTS, respectively. The antitumor activity of the compounds against human cancer cell lines, such as breast MCF-7, liver HepG2, and cervical Hela, was determined by a standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Three compounds had moderate IC50 values. Interestingly, compound 3f had better biological activity than hesperetin, which matches the prediction by Maestro from Schrödinger. Therefore, the new hesperidin derivative is a promising drug for the treatment of cancer due to its effective antitumor activity. The results also suggested that the antitumor activities of hesperetin derivatives may be related to their antioxidant activities.Entities:
Keywords: aminobenzene methylation; antioxidant activity; antitumor activity; hesperetin derivatives; molecular docking; structure–activity relationships
Mesh:
Substances:
Year: 2022 PMID: 35164142 PMCID: PMC8839103 DOI: 10.3390/molecules27030879
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Substrate scope of aminobenzene methylation of hesperetin 2 (Reaction conditions: hesperetin 2 (2 mmol), benzaldehyde (2 mmol), amine (3 mmol), and methanol (40 mL) at 40 ℃ for 8 h. Isolated yields.
Antioxidant activities of hesperetin and its derivatives by DPPH and ABTS assays.
| Samples | DPPH IC50 μM | ABTS IC50 μM |
|---|---|---|
|
| 70 ± 1 | 276 ± 5 |
|
| 16 ± 1 | 105 ± 2 |
|
| 16 ± 1 | 104 ± 2 |
|
| 22 ± 1 | 114 ± 2 |
|
| 26 ± 0. | 161 ± 3 |
|
| 1.7 ± 0 | 45 ± 1 |
|
| 1.2 ± 0 | 24 ± 0 |
|
| 11 ± 0 | 64 ± 0 |
|
| 10 ± 0 | 70 ± 1 |
|
| 10 ± 0 | 62 ± 0 |
|
| 26 ± 0 | 224 ± 3 |
|
| 1.2 ± 0 | 27 ± 0 |
| Vc | 59 ± 1 | 236 ± 1 |
Figure 1(a) Surface view of molecular docking of compound 2 with E6 protein, (b) two-dimensional image of type of interactions with the residues of 3f with E6 protein.
Inhibition rates at 50 μM (%) of compounds 2 and 3a–3k in three cancer cell lines. (The treatment time used in cytotoxicity studies is 48 h).
| Compounds | MCF-7 | HepG2 | HeLa |
|---|---|---|---|
|
| 26 ± 6 | 54 ± 2 | 20 ± 1 |
|
| 30 ± 2 | 52 ± 1 | 31 ± 7 |
|
| 25 ± 2 | 46 ± 2 | 33 ± 7 |
|
| 28 ± 2 | 30 ± 5 | 26 ± 2 |
|
| 15 ± 7 | 44 ± 1 | 25 ± 2 |
|
| 68 ± 2 | 63 ± 0 | 70 ± 1 |
|
| 77 ± 1 | 69 ± 1 | 74 ± 0 |
|
| 52 ± 1 | 48 ± 2 | 45 ± 2 |
|
| 23 ± 1 | 41 ± 5 | 22 ± 2 |
|
| 36 ± 7 | 53 ± 1 | 53 ± 2 |
|
| 19 ± 2 | 39 ± 7 | 32 ± 4 |
|
| 56 ± 1 | 63 ± 2 | 61 ± 3 |
| Cisplatin | 78 ± 1 | 86 ± 1 | 82 ± 1 |
IC50 value (μM) of the screened compounds in three cancer cell lines. (The treatment time used in cytotoxicity studies is 48 h).
| Compounds | MCF-7 | HepG2 | HeLa |
|---|---|---|---|
|
| >50 | 50 ± 2 | >50 |
|
| 15 ± 2 | 43 ± 2 | 19 ± 1 |
|
| 5.3 ± 0 | 8.8 ± 1 | 8.6 ± 1 |
|
| 48 ± 3 | >50 | >50 |
|
| >50 | 34 ± 0 | 46 ± 1 |
|
| 48 ± 1 | 11 ± 2 | 17 ± 6 |
|
| >50 | >50 | >50 |
| Cisplatin | 3.5 ± 0 | 1.1 ± 0 | 1.4 ± 0 |
Figure 2Schematic diagram of structure-activity relationship of compound 3f.